A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With MVA-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in HIV-1 Infected Adults on Suppressive ART
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Ad26 Mos4 HIV (Primary) ; MVA-Mosaic-HIV-vaccine-Janssen-Vaccines-and-Prevention (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Janssen Vaccines and Prevention B.V
- 18 Oct 2017 Planned End Date changed from 19 Feb 2020 to 9 Mar 2020.
- 18 Oct 2017 Planned initiation date changed from 30 Oct 2017 to 14 Feb 2018.
- 16 Oct 2017 New trial record